Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The Tumor Protein D52 (TPD52) gene is located on chromosome 8q21, a region often amplified in human cancers.
• TPD52 is implicated as a potential therapeutic target for novel anticancer strategies.

Purpose of the Study:

• To investigate TPD52 mRNA expression across a wide spectrum of prevalent human cancer types.
• To identify specific cancer types with significant TPD52 upregulation or downregulation.

Main Methods:

• Quantitative PCR (qPCR) was utilized to measure TPD52 mRNA levels.
• Analysis was performed on over 900 formalin-fixed tissue samples from 29 distinct human cancer types.
• TPD52 expression in tumor tissues was compared to corresponding normal tissues.

Main Results:

• TPD52 was expressed in all tested normal tissues.
• Upregulation of TPD52 was observed in 62% (18/29) of cancer types analyzed.
• The highest TPD52 overexpression was detected in non-seminoma, seminoma, ductal breast cancer, and lobular breast cancer.
• Downregulation of TPD52 was found in 38% (11/29) of cancer types, notably papillary and clear cell renal cell carcinoma, leiomyosarcoma, liposarcoma, and lung cancer.

Conclusions:

• TPD52 exhibits frequent and significant differential expression across numerous human cancers.
• The observed upregulation in specific tumor types suggests TPD52 as a promising candidate for targeted anticancer therapies.